Clinical Trial

Ipilimumab (N01) Plus Sintilimab and Modified XELOX as Conversion Therapy in Unresectable Locally Advanced Gastric Cancer

Study acronym: DIAMC-GC
Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study was a prospective, single-arm, multi-center, phase Ⅱ clinical study to investigate the efficacy and safety of ipilimumab injection N01 combined with sintilimab and modified XELOX conversion therapy in patients with unresectable locally advanced gastric cancer who had not received systemic treatment.
Trial Details
NCT Number NCT07638631
Lead Sponsor Chen Lizhu
Conditions Locally Advanced Gastric Cancer
Enrollment 30 participants
Start Date 2026-06-15
Primary Completion 2028-12-31 (estimated)
Study Completion 2030-06-15 (estimated)
Updated on ClinicalTrials.gov 2026-06-10